Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.
Aesthet Surg J. 2019 Jan 31;39(Suppl_1):S21-S27. doi: 10.1093/asj/sjy229.
The exact cellular origins of most malignancies are unknown, largely because of the complex nature of malignancies, and because the potential vast number of pathways towards transformation are difficult to discern from established growths. This is compounded by the fact that cancer cells have evolved rather than being the consequence of a design process, with most data collected from (sometimes epidemiological) studies of large numbers of related malignancies. In the case of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the relative rarity of this disease, coupled with limited insight into its biological basis, have hampered progress. The known facts that are holding up as our knowledge increases with rising incidences are that most cases have been reported in the context of textured breast implants, although not all women with these implants develop BIA-ALCL, and cure for early-stage disease (accounting for the majority of patients) can be achieved via complete capsulectomy and implant removal. However, some theories can be gleaned from the limited biological studies conducted to date whereby a T-helper cell derivation is implicated, with its specific and apparent subset of origin dependent on, and shaped by, a number of factors, including the inflammatory microenvironment (the presence of other inflammatory cell types), the driving antigen (bacterial and/or synthetic), the acquisition of driving oncogenic events, and the inherent genetics/health status of the patient.
大多数恶性肿瘤的确切细胞起源尚不清楚,主要是因为恶性肿瘤的复杂性,以及潜在的大量转化途径很难与已建立的生长区分开来。由于癌细胞是进化而来的,而不是设计过程的结果,而且大多数数据都是从大量相关恶性肿瘤的(有时是流行病学)研究中收集的,因此情况更加复杂。在乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)的情况下,这种疾病相对罕见,加上对其生物学基础的了解有限,阻碍了进展。随着发病率的上升,已知的事实正在不断增加,即大多数病例都报告在纹理乳房植入物的背景下,尽管并非所有这些植入物的女性都会发生 BIA-ALCL,并且早期疾病(占大多数患者)可以通过完全包膜切除术和植入物去除来治愈。然而,从迄今为止进行的有限的生物学研究中可以得出一些理论,其中涉及 T 辅助细胞的起源,其特定和明显的起源子集取决于多种因素,包括炎症微环境(存在其他炎症细胞类型)、驱动抗原(细菌和/或合成)、获得驱动致癌事件以及患者的固有遗传/健康状况。